A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Emergence of additional cytogenetic clones in chronic myelocytic leukemia (CML) patients who become Philadelphia chromosome-negative (Ph-) after alpha-interferon therapy (or more recently with imatinib mesylate) have been described. We report here a case of a novel t(6;7)(p21;q23) that developed in a CML patient in complete cytogenetic remission during imatinib therapy. In this case, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction showed a normal pattern for BCR and ABL genes, suggesting that a different and unrelated clone developed after the disappearance of the Ph chromosome.
Gozzetti
Alessandro
A
Division of Hematology and Transplants, Department of Medicine and Immunological Sciences, University of Siena, Policlinico Le Scotte, 53100 Siena, Italy. gozzetti@unisi.it
Tozzuoli
Daniela
D
Crupi
Rosaria
R
Fanelli
Albertina
A
Gentili
Sara
S
Bocchia
Monica
M
Mazzotta
Serena
S
Raspadori
Donatella
D
Lauria
Francesco
F
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D002896:Chromosomes, Human, Pair 6; D002897:Chromosomes, Human, Pair 7; D006801:Humans; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012074:Remission Induction; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate